Stocklytics Platform
Asset logo for symbol RYTM
Rhythm Pharmaceuticals
RYTM61
$57.23arrow_drop_down0.55%-$0.32
High Growth
Asset logo for symbol RYTM
RYTM61

$57.23

arrow_drop_down0.55%
Key Stats
Open$57.61
Prev. Close$57.52
EPS-4.32
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
PE Ratio-
LOWHIGH
Day Range54.63
57.71
52 Week Range21.34
68.48
Ratios
EPS-4.32
Fundamentals
Payout Ratio-
Industry average yield2.87%
Last Dividend pay date-
Dividend per share-
Dividend yield forecast-

Stock Analysis

Technicals

Summarizing what the indicators are suggesting.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Analyst rating

An aggregate view of professional's ratings.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Stock Performance

RYTM-
US Healthcare Sector-
US Market-
check_circle

RYTM / Market

RYTM exceeded the US Market which returned -1.04% over the last twenty four hours.
warning

RYTM / Healthcare Sector

RYTM lose to the US Healthcare sector which returned 1.84% over the last twenty four hours.

Rhythm Pharmaceuticals (RYTM) Statistics

Rhythm Pharmaceuticals Inc (RYTM) is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of rare genetic disorders of obesity. The company's lead product candidate is setmelanotide, which is being evaluated in clinical trials for the treatment of two rare genetic disorders: Bardet-Biedl syndrome (BBS) and Alström syndrome. These disorders are characterized by severe obesity and hyperphagia, or excessive hunger. Rhythm Pharmaceuticals aims to address the underlying cause of obesity in these patient populations by targeting the melanocortin-4 receptor (MC4R) pathway, which plays a key role in regulating energy balance and appetite.
When it comes to the valuation metrics of Rhythm Pharmaceuticals Inc (RYTM), the company has a market capitalization of $1.24 billion. The stock currently trades at a price-to-sales (P/S) ratio of 70.88, indicating that investors are willing to pay a premium for the company's revenue. In terms of fundamentals, Rhythm Pharmaceuticals Inc has a profit margin of -509.63%, indicating that the company is currently operating at a loss. The company's total debt stands at $0, and it has a gross profit of $1.61 million.
add Rhythm Pharmaceuticals  to watchlist

Keep an eye on Rhythm Pharmaceuticals

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

How has Rhythm Pharmaceuticals (RYTM) stock's performance compared to its sector and the market over the past year?

Over the past year, Rhythm Pharmaceuticals (RYTM) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 23.95%, Rhythm Pharmaceuticals has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 48.40%, it has fallen short of the market average. This comparison highlights Rhythm Pharmaceuticals 's performance relative to both its sector and the overall market over the last year.
help

What is the PE ratio of Rhythm Pharmaceuticals (RYTM) stock?

The PE ratio for Rhythm Pharmaceuticals (RYTM) is currently not available. This could be due to a variety of factors such as the company not having positive earnings at the moment or recent updates not being reflected.
help

What is the EPS of Rhythm Pharmaceuticals (RYTM) stock?

The Earnings Per Share (EPS) for Rhythm Pharmaceuticals (RYTM), calculated on a diluted basis, is -$4.32. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.
help

What is the operating margin of Rhythm Pharmaceuticals (RYTM) stock?

The operating margin for Rhythm Pharmaceuticals (RYTM) is -131.98%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.
help

What is the EBITDA of Rhythm Pharmaceuticals (RYTM) stock?

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of Rhythm Pharmaceuticals (RYTM) is -$263.92M. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.
help

How much debt does Rhythm Pharmaceuticals (RYTM) have?

Rhythm Pharmaceuticals (RYTM) has a total debt of $113.27M. The net debt, which accounts for cash and cash equivalents against the total debt, is -$43.49M.

Take Your Investments to a Whole New Level